Seasonal Influenza Vaccine 2021/2022 Provides Limited Cross Reactivity Against Contemporary Swine Influenza A Virus Strains in Spain
Swine influenza A viruses (SIVs) pose a zoonotic risk, with variants detected in humans in Europe. This study evaluated the efficacy of the 2021/2022 seasonal influenza vaccine against SIVs. Forty-six postvaccination human sera were tested via hemagglutination inhibition (HI) assay against Spanish S...
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/417011 |
| Acceso en línea: | http://hdl.handle.net/10261/417011 https://api.elsevier.com/content/abstract/scopus_id/105025436413 |
| Access Level: | acceso abierto |
| Palabra clave: | Influenza A virus Pandemic risk Reverse zoonosis Swine Vaccine |
| Sumario: | Swine influenza A viruses (SIVs) pose a zoonotic risk, with variants detected in humans in Europe. This study evaluated the efficacy of the 2021/2022 seasonal influenza vaccine against SIVs. Forty-six postvaccination human sera were tested via hemagglutination inhibition (HI) assay against Spanish SIV genotypes. Seroprotection rate (SPR, HI titer ≥ 40) was 76% (95% CI: 64–88) and 91% (95% CI: 83–99) for human vaccine strains H1 and H3, respectively. SPRs were 67% (95% CI: 53–81) for pandemic swine H1, 64% (95% CI: 50–78) for human seasonal-like H1, 17%–46% for Eurasian avian-like H1, 15% (95% CI: 5–25) for human seasonal-like H3 from the 1970s, and 83%–93% for human seasonal-like H3 from the 2000s SIVs. |
|---|